Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.80 from $3.50 and keeps a Hold rating on the shares. The firm said its target decrease reflects multiple headwinds including tariffs, funding uncertainty, recession fears, and China.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya expands portfolio with new ADC breast cancer assay at AACR 2025
- Akoya Biosciences, Enable Medicine launch single-cell spatial proteomics atlas
- Akoya Biosciences, STCC partner on SUPER study for cancer immunophenotyping
- Akoya Biosciences price target lowered to $1.65 from $2.40 at Piper Sandler
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion